Latest Internet Technology for the Replacement of Animal Experiments

Developed in close cooperation between Transinsight, Dresden, and the German Federal Institute for Risk Assessment, Berlin, the knowledge-based semantic search engine www.Go3R.org is now available online. It enables information transparency for the prevention of animal testing.

In only four months development time, Transinsight from Dresden, Germany, succeeded in making available online Go3R, the worldwide first knowledge-based search engine for alternative methods to animal experiments. Via www.Go3R.org, scientists from all over the world can take advantage of the benefits of semantic searches for the area of alternative methods in accordance with the 3Rs principle. The Search engine can from now on used as Beta version.

The so-called 3Rs principle developed by Russell and Burch in 1959 stands for Replacement, Reduction and Refinement. It describes scientific methods that can either replace animal experiments, or reduce animal numbers or refine the suffering of the animals during the procedures. In the European Union, compliance with the 3Rs principle is legally required. In accordance with the EU Laboratory Animal Directive, just as with the German Animal Welfare Act, animal experiments may only be performed if the scientific goal pursued cannot be achieved by any other means, i.e. in totally non-animal procedures, or in methods using fewer animals or entailing less animal suffering.

In practice, however, this legal requirement oftentimes is not met, because the scientists and the responsible authorities are unaware of 3Rs alternatives that would exist to the respective foreseen animal experiment. Queries for alternative methods are time consuming and cumbersome, and this situation has possibly even become worse in the era of the internet. Additionally, at the end of a search, it remains unclear whether all relevant information sought for was indeed retrieved. This is where the search engine Go3R sets in.

"With Go3R, search retrievals for alternatives to animal experiments become transparent and they are available without delay. Time savings of 90 percent and more are already possible with the first prototype of the search engine", explains Dr. Michael R. Alvers, CEO and Co-Founder of Transinsight. "With our information technology Go3R, we are pleased to be able to present scientists with a tool that enables them to determine the indispensability of animal experiments more reliably. Go3R promotes the 3Rs principle. In the medium term, this will lead to a significant reduction of animal experiments. Achieving a world with less and less animal experiments is the worthwhile goal that Transinsight is happy to make a contribution to with all its might", says Alvers.

Go3R was developed in cooperation with scientists from the Technical University Dresden and the National German Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET) at the German Federal Institute for Risk Assessment in Berlin. With its expertise in the area of alternative methods, ZEBET has provided the specialist know how for the search machine.

"Already today, Germany is leading in the area of development of alternative methods. The new search engine will make a contribution further to promote Germany's international reputation. The combination of ZEBET's expertise - acquired over decades - with latest semantic search technologies will lead to a new generation of science as regards avoidance of animal experiments", declares Professor Dr. Horst Spielmann, international scientist of excellence in the area of alternative methods and for many years, Head of ZEBET.

In a next step, the search engine www.Go3R.org is now being extended to become a community platform enabling global cooperation without language barriers. It is the goal of the investment to achieve maximum availability of information with simultaneous transparency for scientists and researchers all over the world. The service is available free of charge.

Related news articles:

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.GoPubMed.com, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden.

For more information about Transinsight, visit www.transinsight.com.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...